Healionics is a clinical-stage company addressing the critical need for improved means of dialysis access in patients with kidney failure.  Our STARgraft vascular graft (artificial blood vessel) resists the problems of occlusion and infection suffered by current grafts.  We also have an exciting product pipeline based on our platform STAR® biomaterial which, given its unique ability to prevent both scarring and infection, can enable new types of implantable devices and improve the performance of many existing ones.  The company has 33 patents issued or pending.

Our Seattle location has facilitated strong connections and collaboration with several organizations that have pioneered the life-saving devices and clinical innovations needed to treat kidney failure with dialysis.  These include University of Washington (where the first device for long-term blood access and early dialysis machines were invented), Northwest Kidney Centers (the world’s first outpatient dialysis center), Kidney Research Institute, and Center for Dialysis Innovation.